omniture

Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging

Miltenyi Biotec GmbH
2010-06-15 15:03 6768

BERLIN and BERGISCH GLADBACH, Germany, June 16 /PRNewswire-Asia/ --

Miltenyi Biotec today announces the worldwide release of the Viscover(TM)

product line, offering researchers an unrivaled range of preclinical contrast

agents for small animal in vivo imaging.

Viscover marks the result of a fruitful collaboration between Miltenyi

Biotec GmbH and nanoPET Pharma GmbH. Within this strategic alliance, Miltenyi

Biotec is responsible for the distribution of Viscover products developed and

manufactured by nanoPET Pharma. The current Viscover portfolio comprises

twenty-one contrast agents for the preclinical imaging modalities MRI, CT,

Optical Imaging, Ultrasound and SPECT/PET, and this number is set to increase

soon.

"This partnership offers researchers a unique and powerful portfolio of

small animal in vivo imaging agents," explains Stefan Miltenyi, CEO of

Miltenyi Biotec. "Both nanoPET Pharma and Miltenyi Biotec are committed to

serving the biomedical research community with innovative high-quality

imaging products throughout the world."

Commenting on the collaboration, Andreas Briel, CEO of nanoPET Pharma

GmbH, said: "This landmark partnership brings together Miltenyi Biotec's

excellence in worldwide customer support with nanoPET's exclusive range of

contrast agents. Our scientists have years of experience in biomedical

imaging, gained through strong affiliations with commercial and academic

bodies."

About Miltenyi Biotec

Miltenyi Biotec's company mission is to improve scientific understanding

and medical progress by providing products and services for cellular

therapies. With approx. 1100 employees in 18 countries, Miltenyi Biotec

develops, manufactures, and commercializes innovations for both research and

clinical applications. The portfolio provides integrated solutions for all

areas covering sample preparation, cell separation, cell culture, flow

cytometry, and molecular analysis.

Visit http://www.miltenyibiotec.com to learn more.

About nanoPET Pharma

Based in Berlin, nanoPET Pharma GmbH discovers and develops innovative

pharmaceutical contrast agents for use with the complete range of

preclinical imaging modalities. The comprehensive Viscover portfolio

currently provides contrast agents for the MRI, CT, Ultrasound, Optical

Imaging, SPECT and PET modalities.

Visit http://www.viscover.com to discover more.

Contact:

Miltenyi Biotec

Prof. Dr. Uwe Heinlein, Corporate Communications,

Miltenyi Biotec GmbH, +49-2204-8306-6590,

uweh@miltenyibiotec.de

nanoPET Pharma

Carolin Schlueter, Corporate Communications,

nanoPET Pharma GmbH, +49-30-890-49-740,

Carolin.Schlueter@nanopet.de

Source: Miltenyi Biotec GmbH
collection